Literature DB >> 10424295

Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a steroid-resistant transplant rejection episode.

A W Lohse1, P Obermayer-Straub, G Gerken, S Brunner, U Altes, H P Dienes, M P Manns, K H Meyer zum Büschenfelde.   

Abstract

BACKGROUND/AIMS: Antibodies to cytochrome P450 2D6, also known as LKM1-autoantibodies, are characteristic for a subgroup of patients with autoimmune hepatitis, but can also occasionally be found in hepatitis C. We observed the occurrence of LKM1-autoantibodies 4 months after liver transplantation for Wilson's disease, in close association with a steroid-resistant rejection episode, in the absence of evidence for autoimmune hepatitis or hepatitis C.
METHODS: Sera from several time points prior to and following transplantation were tested for LKM-reactivity by immunofluorescence, ELISA and Western blotting. Antigen specificity was confirmed by Western blotting analysis on different cytochrome P450 isoenzymes. The absence of viral hepatitis C and hepatitis G virus infection was confirmed by polymerase chain reaction. The serum of the organ donor was also tested.
RESULTS: All the sera prior to transplantation and up to 4 months after transplantation were LKM-negative by all assay systems used. In the course of a steroid-resistant rejection episode at this time, the patient developed LKM antibodies at high titre (70% in inhibition ELISA) and has remained positive since (now more than 4 years). Reactivity was exclusively to the cytochrome isoenzyme 2D6. Hepatitis C infection never occurred, but hepatitis G was transiently present many years prior to transplantation. The donor serum was negative for all autoantibodies and for hepatitis C and G virus infection. DISCUSSION: We here describe a patient developing LKM1-autoantibodies without evidence of autoimmune or viral hepatitis. The close temporal association with a transplant rejection episode suggests immunological mechanisms of rejection together with hepatocellular injury as a pathogenetic mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424295     DOI: 10.1016/s0168-8278(99)80175-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

Review 1.  Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for regulation and therapy of liver auto- and alloimmunity.

Authors:  Sudha Natarajan; Angus W Thomson
Journal:  Immunobiology       Date:  2010-06-22       Impact factor: 3.144

2.  Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.

Authors:  S D Lytton; U Berg; A Nemeth; M Ingelman-Sundberg
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

4.  Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.

Authors:  M Baeres; J Herkel; A J Czaja; I Wies; S Kanzler; E L R Cancado; G Porta; M Nishioka; T Simon; C Daehnrich; W Schlumberger; P R Galle; A W Lohse
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

Review 5.  Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

Review 6.  Recurrence of autoimmune liver diseases after liver transplantation: clinical aspects.

Authors:  Evangelos Cholongitas; Andrew K Burroughs
Journal:  Auto Immun Highlights       Date:  2012-10-30

7.  Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?

Authors:  Maria Grazia Clemente; Roberto Antonucci; Claudia Mandato; Lucia Cicotto; Antonella Meloni; Bruno Gridelli; Stefano De Virgiliis; Michael P Manns; Pietro Vajro
Journal:  Biomed Res Int       Date:  2017-11-27       Impact factor: 3.411

8.  Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis.

Authors:  Laura Elisa Buitrago-Molina; Janine Dywicki; Fatih Noyan; Martin Trippler; Julia Pietrek; Jerome Schlue; Michael P Manns; Heiner Wedemeyer; Elmar Jaeckel; Matthias Hardtke-Wolenski
Journal:  Biomedicines       Date:  2021-01-09

9.  Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.

Authors:  Hind I Fallatah; Hisham O Akbar
Journal:  Autoimmune Dis       Date:  2012-12-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.